Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00007683 · ClinicalTrials.gov registry record · Phase 3
Warfarin and Antiplatelet Therapy in Chronic Heart Failure
A Phase 3 study of Heart Failure, sponsored by US Department of Veterans Affairs.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,587
- Enrollment target
- 20
- Study locations
NCT00007683: Completed Phase 3 study of Heart Failure, sponsored by US Department of Veterans Affairs.
NCT00007683 is a Phase 3 study of Heart Failure that has completed, run by US Department of Veterans Affairs. The registered enrollment target is 1,587 participants, below the 2,045-participant average among 397 other Heart Failure trials with a reported enrollment target (22% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00007683, a Phase 3 study of Heart Failure, has completed, sponsored by US Department of Veterans Affairs.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,587 participants
- Enrollment target
- 20
- Study locations
Study Summary
Whether patients with chronic heart failure (CHF) should be anticoagulated is one of the oldest unresolved questions in cardiovascular therapeutics. Some authorities do not recommend anticoagulation for CHF patients in sinus rhythm, others recommend anticoagulation in patients with primary cardiomyopathy, and still others consider it more appropriate in patients with coronary artery disease (CAD). This absence of consensus reflects the lack of evidence in this area and different outlooks on the objectives of such therapy (e.g., prevention of arterial emboli or reduction in vascular events).
Primary Outcome
The primary safety end point was major bleeding episodes, defined as bleeding episodes leading to death or disability (including loss of neurological or special senses function), requiring surgical intervention, or associated with an acute decline of hemoglobin 2gm/dl or transfusion of \>1 U packed red cells or whole blood.
Conditions Studied
Interventions
- DRUG Aspirin
- DRUG Warfarin titrated to an INR of 2.5-3.0
- DRUG Clopidogrel 75
Study Locations (20)
California
- Rancho Los Amigos National Rehabilitation Center - Downey
- VA Central California Health Care System, Fresno - Fresno
- VA Medical Center, Loma Linda - Loma Linda
- VA Palo Alto Health Care System - Palo Alto
- VA Medical Center, San Francisco - San Francisco
- VA Greater Los Angeles HCS, Sepulveda - Sepulveda
- Cardiovascular Consultants, Walnut Creek - Walnut Creek
- VA Greater Los Angeles Healthcare System, West LA - West Los Angeles
Connecticut
- Cardiology Associates of Derby, P.C. - Derby
- St. Francis Hospital and Medical Center - Hartford
- VA Connecticut Health Care System (West Haven) - West Haven
Florida
- Florida Cardiovascular Research - Atlantis
- VA Medical Center, Bay Pines - Bay Pines
- North Florida/South Georgia Veterans Health System - Gainesville
Arizona
- Carl T. Hayden VA Medical Center - Phoenix
- Southern Arizona VA Health Care System, Tucson - Tucson
Alabama
- VA Medical Center, Birmingham - Birmingham
Arkansas
- Central Arkansas VHS Eugene J. Towbin Healthcare Ctr, Little Rock - No. Little Rock
Colorado
- VA Eastern Colorado Health Care System, Denver - Denver
District of Columbia
- VA Medical Center, DC - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,587 participants |
| Start Date | 1998-10 |
| Est. Completion | 2004-12 |
| Phase | Phase 3 |
What the finished NCT00007683 record still lists
NCT00007683 is an interventional study that assigns participants to a tested intervention. Its 1,587 participants enrollment target places it among the larger protocols in the corpus, below the 2,045-participant average among 397 other Heart Failure trials with a reported enrollment target (22% lower).
The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 3 interventions - of which Aspirin is the first listed.
NCT00007683 names 20 study sites across 8 states, led by California, Connecticut, Florida.
Frequently Asked Questions
What is clinical trial NCT00007683 about?
NCT00007683 is a clinical study titled "Warfarin and Antiplatelet Therapy in Chronic Heart Failure". Whether patients with chronic heart failure (CHF) should be anticoagulated is one of the oldest unresolved questions in cardiovascular therapeutics. Some authorities do not recommend anticoagulation for CHF patients in sinus rhythm, others recommend anticoagulation in patients with primary cardiomyo...
What is the current status of trial NCT00007683?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,587 participants. The study started on 1998-10. Estimated completion is 2004-12.
What conditions does trial NCT00007683 study?
This clinical trial studies the following conditions: Heart Failure.
What interventions are being tested in trial NCT00007683?
The interventions under investigation include: Aspirin (DRUG), Warfarin titrated to an INR of 2.5-3.0 (DRUG), Clopidogrel 75 (DRUG).
Who is sponsoring clinical trial NCT00007683?
This trial is sponsored by US Department of Veterans Affairs, which has 632 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00007683 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00007683's enrollment target sits among peer trials
1,587 52nd of 397 higher than 346 of 397 other Heart Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists
RECRUITING · Phase 3
-
Home-based Cardiac Rehabilitation in Heart Failure
RECRUITING · Phase 3
-
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients with Heart Failure (CONFIRMATION-HF)
RECRUITING · Phase 3
-
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
RECRUITING · Phase 3
-
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
RECRUITING · Phase 3
-
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05552222 · 1,590 participants · Phase 3
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- NCT06632457 · 1,590 participants · Phase 3
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
- NCT05243797 · 1,594 participants · Phase 3
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- NCT05483855 · 1,580 participants
Telehealth-delivered HealthcaRe to ImproVe Care
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia